Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $4.0 million.

  • Keros Therapeutics' Share-based Compensation fell 5479.19% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.6 million, marking a year-over-year decrease of 728.88%. This contributed to the annual value of $34.9 million for FY2024, which is 2123.91% up from last year.
  • Per Keros Therapeutics' latest filing, its Share-based Compensation stood at $4.0 million for Q3 2025, which was down 5479.19% from $8.5 million recorded in Q2 2025.
  • Over the past 5 years, Keros Therapeutics' Share-based Compensation peaked at $9.2 million during Q4 2024, and registered a low of $2.5 million during Q1 2021.
  • For the 5-year period, Keros Therapeutics' Share-based Compensation averaged around $6.1 million, with its median value being $5.7 million (2023).
  • As far as peak fluctuations go, Keros Therapeutics' Share-based Compensation soared by 2068333.33% in 2021, and later plummeted by 5479.19% in 2025.
  • Over the past 5 years, Keros Therapeutics' Share-based Compensation (Quarter) stood at $3.3 million in 2021, then soared by 44.04% to $4.7 million in 2022, then skyrocketed by 54.32% to $7.3 million in 2023, then increased by 25.61% to $9.2 million in 2024, then tumbled by 56.67% to $4.0 million in 2025.
  • Its Share-based Compensation stands at $4.0 million for Q3 2025, versus $8.5 million for Q2 2025 and $8.9 million for Q1 2025.